Immunovaccine receives thumbs up for Ph1/2 ovarian cancer trial, NanoBio starts second intranasal flu vax trial;

Vaccine Research

Immunovaccine has received FDA clearance for a Phase I/II trial for DPX-Survivac as an ovarian cancer treatment. The company plans to start the Phase I trial in the fourth quarter of 2011. Immunovaccine release

Ann Arbor, MI-based NanoBio has started a Phase Ib trial to test the immunogenicity and tolerability of its nanoemulsion intranasal flu vaccine approach using Fluzone. NanoBio release

Inviragen has started a Phase I trial for its hand, foot and mouth disease vaccine in Singapore. Story

Hemispherx and the University of Pennsylvania School of Medicine have entered a research agreement to study Ampligen as a vaccine adjuvent treating ovarian cancer in a Phase I/II study. Hemispherx release

Vaccine Market

The Defense Advanced Research Projects Agency (DARPA) has awarded Medicago with $5.6 million for its flu vaccine manufacturing plant under construction in Research Triangle Park, NC. Medicago has received $16.3 million so far for the facility, and stands to receive $21 million overall. Article

According to Rwanda's Ministry of Health, the country has reached 97 percent coverage in the first phase of HPV vaccinations. The vaccination effort targets girls ages 12 to 15, who will still receive another two doses of the vaccine. News

And Finally... A study shows that babies born to women who received flu vaccinations are 50 percent less likely to be hospitalized than those born to unvaccinated mothers. Article

Suggested Articles

GSK's Shingrix supply has recovered after COVID-19 prompted a slowdown in vaccinations.

To eradicate SARS-CoV-2, we'll need a vaccine that's 70% effective—and 70% of the population will need to receive it, an FDA official says.

The U.K. government, fearing losing the supply race, agreed to buy 60 million doses of GSK-Sanofi's COVID-19 vaccine even before phase 1.